Background Acquired thrombotic thrombocytopenic purpura (TTP) is caused by aggregation
of platelets on ultralarge von Willebrand factor multimers. This microvascular thrombosis …

… with a reduction in caplacizumab cost demonstrating the … caplacizumab in 100% of 10 000
iterations. Our data indicate that the addition of caplacizumab to SOC in treatment of acquired …

… Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition.
In 2018, the nanobody caplacizumab … on the use of caplacizumab in 60 patients from 29 …

… with thrombotic thrombocytopenic purpura (TTP). The numbers of patients in the caplacizumab
… The text reports 6 adverse events that were considered to be related to caplacizumab and …

… Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura),
we sought to confirm the potential role of caplacizumab in the treatment of TTP by comparing …

… Caplacizumab prevents platelet adhesion and has been approved for acquired thrombotic
thrombocytopenic purpura … aTTP and treated with caplacizumab since commercial availability …

… of patients experiencing thromboembolic events was lower with caplacizumab as compared
to the placebo (11.4% vs 43.2%) [39]. Though less in number, such thromboembolic events …

… episode of aTTP treated with caplacizumab but without plasma exchange that were identified
retrospectively from a cohort of 60+ patients treated with caplacizumab at 30+ different …

… The pharmacokinetics of caplacizumab are predictable when considering the turn-over of …
of the pharmacodynamic effect of caplacizumab. Expert opinion: Caplacizumab prevents the …

… safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (…
Caplacizumab was associated with a significant reduction in the number of deaths (0 vs 4; P …